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Background: This study aims to investigate the inflammasome response in peripheral blood mononuclear cells
(PBMCs) and the expression of inflammasome components in bone biopsies from patients with chronic recurrent
multifocal osteomyelitis (CRMO).
Methods: The expression of inflammasome components mRNAs was evaluated in PBMCs isolated from 15 CRMO
patients and 13 healthy controls by quantitative real-time PCR. The Interleukin (IL)-1β released in the medium
of PBMC cultures after treatment with lipopolysaccharides (LPS) alone or LPS and ATP was measured by ELISA.
Immunohistochemical staining for Apoptosis-associated Speck-like protein (ASC), caspase-1 (CASP-1), Nod-like
receptor protein-3 (NLRP3) and IL-1β expression was performed in bone biopsies from CRMO patients.
Results: mRNA levels of ASC, CASP-1 and IL-1β were significantly higher in freshly isolated PBMCs from CRMO
patients in active disease than in healthy controls. CASP-1 and IL-1β transcript levels were significantly higher also
in PBMCs from CRMO patients in remission compared to healthy controls. PBMCs from CRMO patients in active
disease stimulated in vitro with LPS showed a significant increase in IL-1β release compared to healthy control
cells. Immunohistochemistry staining of bone tissue revealed the expression of inflammasome components in
CRMO osteoclasts.
Conclusions: Our data suggest that an abnormal regulation of IL-1β axis may be involved in CRMO pathogenesis.
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OsteoclastsBackground
Chronic recurrent multifocal osteomyelitis (CRMO) is a
rare skeletal disorder, predominantly affecting children,
that presents with bone pain, fever and sterile multifocal
osteolytic bone lesions, characterized by inflammatory
infiltrate and activated osteoclasts [1].
Osteoclasts belong to the monocyte-macrophage lineage,
are responsible for bone resorption and are regulated by
pro-inflammatory cytokines [2]. CRMO is usually sporadic,
but there is evidence of a genetic component, as several
reports described the disease in siblings and in monozy-
gotic twins [3]. Moreover, a monogenic disease associated
with CRMO, termed Majeed’s Syndrome, is known [4].* Correspondence: fabrizio.debenedetti@opbg.net
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disease, the pathogenetic mechanisms are still unknown.
Recent findings demonstrate, in a murine model of CRMO,
an inflammasome-independent role for the interleukin-1
(IL-1) pathway in the disease pathogenesis [5]. In patients
with CRMO, an imbalance between pro-inflammatory
(IL-6, TNF-α) and anti-inflammatory cytokines (IL-10)
has been hypothesized to be involved [6]. Autoinflam-
matory diseases are characterized by deregulation of the
innate immune system, often involving the IL-1β pathway
[7]. Release of IL-1β is induced by inflammasomes, multi-
protein cytoplasmic complexes, composed by pattern rec-
ognition receptors, including Toll-like receptors (TLRs)
and Nod-like receptors, the adaptor protein Apoptosis-
associated speck-like protein containing a CARD (ASC)
and pro-caspase-1, that sense microbial molecules and
endogenous danger signals [8].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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provided by microbial or endogenous molecules that
activate NF-κB and induce, through a TLR, expression
and synthesis of the inactive IL-1β precursor (pro-IL-1β).
The second signal is provided by adenosine triphosphate
(ATP), certain bacterial toxins or particulate matter and
directly activates inflammasomes, resulting in pro-IL-1β
cleavage and IL-1β secretion [8].
The aim of this study was to examine the inflammasome
response in peripheral blood mononuclear cells (PBMCs)
and the expression of inflammasome components in bone
biopsies from CRMO patients.
Methods
Subjects
Peripheral blood was obtained from 15 patients with
CRMO. The diagnosis of CRMO was based on clinical
presentation, laboratory and imaging data and bone bi-
opsy. Bone biopsies (obtained from all patients, except
one) showed evidence of sterile bone inflammation.
At the time of the study, 7 patients had active dis-
ease, defined by patients’ reported bone and/or joint
pain, increased C-reactive protein (CRP) (normal
<0.5 mg/dl) or erythrocyte sedimentation rate (ESR)
(normal <20 mm/h) and lesions demonstrating in-
creased uptake of technetium-99 m in bone scan. The
main characteristics of CRMO patients in active dis-
ease were: 5 females and 2 males, mean age at onset
9.57 ± 5.16 years, mean age at sampling 10.31 ±
5.72 years, number of bone lesions from 1 to 6 (me-
dian 3); 5 patients were treated with non steroidal
anti-inflammatory drugs (NSAID) and 2 were not re-
ceiving any treatment. The remaining 8 patients who
did not meet the criteria for active disease were de-
fined as having remission: 4 females and 4 males,
mean age at onset 7.22 ± 4.64 years, mean age at sam-
pling 10.36 ± 5.38 years; 2 patients were treated with
methotrexate, 1 with sulfasalazine and NSAID and
the remaining 5 were not receiving any treatment.
Thirteen healthy children comparable for age, hospital-
ized for minor surgical procedures, were used as controls.
Blood samples were collected before they underwent
surgery. They did not have evidence of infection or in-
flammation or increased CRP at time of blood sampling.
In addition, peripheral blood was obtained also from 7
children with active juvenile idiopathic arthritis (JIA)
(mean age at sampling 8.14 ± 2.54 years). Blood samples
were taken after informed consent of the parents.
The study was approved by the Institutional Ethical
Committee.
PBMC isolation and in vitro stimulation
PBMCs were separated from blood by Ficoll/Histopaque
(Sigma-Aldrich). Freshly isolated PBMCs were incubatedin DMEM (Gibco) plus 10% FBS with 10 ng/ml lipopoly-
saccharides (LPS, E. coli serotype 055:B5, Sigma-Aldrich)
for 3 hours, or stimulated with 10 ng/ml LPS for 2 hours,
followed by stimulation with 2 mM ATP (Sigma-Aldrich)
for 1 hour.
Cytokine detection
Levels of IL-1β in PBMC supernatants were quantified
by ELISA (R&D System). Circulating IL-1β and IL-6
levels were measured in plasma collected from patients
and controls by ELISA, using commercial kits (R&D
System) according to the manufacturer’s instructions.
RNA isolation and real-time PCR
Total RNA was extracted using the Qiagen-RNeasy Mini
kit (Qiagen) from 106 PBMCs and cDNA was obtained
using the Superscript Vilo kit (Invitrogen). Real-time
PCR assays were performed using TaqMan Universal
PCR Master mix (Applied Biosystems) and the following
gene-expression assays: human IL-1β, TNF-α, CASP-1,
ASC and NLRP3 (Applied Biosystem). Gene expression
data were normalized using HPRT, as endogenous con-
trol. Data are expressed as arbitrary units (AU) using the
2-ΔCt transformation method.
Immunohistochemistry
Bone-biopsy specimens were available from three CRMO
patients and were evaluated by immunohistochemistry. A
bone-biopsy from a patient with acute lymphoblastic
leukemia in remission was used as tissue control.
Formalin-fixed, decalcified and embedded in paraffin
bone-biopsy specimens were immunostained with
antibodies to human ASC (LifeSpan BioSciences), NLRP3
(Sigma-Aldrich), CASP-1 (Cell Signaling), IL-1β (Cell
Signaling) and IL-6 (Abcam), revealed by LSAB2
System-HRP (DakoCytomation) and counterstained
with hematoxylin.
Statistical analysis
Quantitative data were expressed as mean ± SD or as
median and interquartile range (IQR). Statistical analysis
was performed by the Mann–Whitney U test. P values
less than 0.05 were considered significant.
Results
ASC, CASP-1 and IL-1β mRNA levels were significantly
higher in PBMCs freshly isolated from CRMO patients
during active disease compared to PBMCs from healthy
controls. The mRNA expression of CASP-1 and IL-1β
was also significantly higher in PBMCs from patients in
remission compared to healthy controls (Figure 1A-D).
No significant difference in TNF-α expression was ob-



































































































































Figure 1 Characterization of PBMCs from CRMO patients. (A-E) Real Time-PCR analysis of gene products involved in the regulation of IL-1β,
including ASC, NLRP3, CASP-1, IL-1β and of the pro-inflammatory cytokine TNF-α in freshly isolated PBMCs obtained from CRMO patients in
remission (gray dots) or with active disease (black dots) and healthy controls (white dots). Values are presented as arbitrary unit (AU). (F-G) IL-1β
released in supernatants by PBMCs isolated from CRMO patients in remission or in active disease and from healthy controls, after stimulation with
10 ng/ml LPS for 3 hours (F) or 10 ng/ml LPS for 2 hours followed by treatment with 2 mM ATP for 1 hour (G). IL-1β was measured by ELISA.
Black lines represent the mean value. *p < 0.05, **p < 0.01 vs healthy controls.
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to measure detectable levels of circulating IL-1β (data
not shown). We found that, compared to healthy con-
trols [median value 0.156 pg/ml, Interquartile range
(IQR) 0.156-0.612], circulating levels of IL-6 were similar
in patients in remission (median value 0.327 pg/ml, IQR
0.156-1.825) (p = 0.14), while they were significantly in-
creased in patients during active disease (median value
8.48 pg/ml, IQR 4.93-23.72) (p = 0.0004).
To evaluate inflammasome activation in PBMCs from
CRMO patients, freshly isolated PBMCs were stimulated
in vitro with LPS alone or LPS plus ATP and the IL-1β
released in the medium was measured. After LPS stimula-
tion, the amount of IL-1β released by PBMCs from
CRMO patients with active disease was significantlyhigher when compared to patients during remission or to
healthy controls (Figure 1F). In contrast, cells from pa-
tients with active JIA stimulated with LPS alone produced
amount of IL-1β comparable to those released by healthy
controls (0.067 ng/ml ±0.061 versus 0.064 ng/ml ±0.046,
p > 0.5). Stimulation with LPS plus ATP led, as expected,
to a marked increase in IL-1β release, with no significant
differences between the three groups (Figure 1G). In
patients with active disease, IL-1β mRNA levels in PBMCs
freshly isolated or IL-1β release following in vitro LPS
stimulation were not significantly associated with the
number of bone lesions (R = 0.480, p = 0.27; R = 0.566,
p = 0.17, respectively) or ESR (R = 0.141, p = 0.75; R = 0.50,
p = 0.24, respectively). In two patients, we analyzed PBMC
IL-1β mRNA levels before and after (16 and 18 days,
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tion in IL-1β mRNA levels was observed (pre-treatment
49.7 and 50.9; post-treatment 28.1 and 23.3 arbitrary unit,
respectively).
The presence of activated osteoclasts is a typical














Figure 2 Expression of inflammasome components and IL-6 in bone b
Representative immunohistochemical staining of decalcified human bone b
with CRMO (AI-BI-CI-DI-EI-FI-GI). Bone sections were stained with hematox
indicated. Magnification: X63. Arrows: osteoclasts.potential pathogenic role in CRMO, we performed
the immunohistochemical staining of bone biopsy
specimens from CRMO patients (n = 3), (Figure 2AI-FI)
and from one tissue control (Figure 2 A-F) with antibodies
to ASC, NLRP3, CASP-1 and IL-1β. In bone tissue from








iopsies from CRMO patients and from one tissue control.
iopsy specimens from a tissue control (A-B-C-D-E-F-G) and patients
ylin-eosin, a secondary antibody only or with primary antibodies as
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detected, demonstrating that also osteoclasts expressed
components of the inflammasome machinery.
Discussion
We demonstrated an abnormal regulation of the IL-1β
axis and its secretory machinery in CRMO patients.
PBMCs from CRMO patients obtained during the active
disease expressed higher mRNA levels of inflammasome
key components, ASC and CASP-1, and higher levels of
IL-1β mRNA. Moreover, PBMCs from CRMO patients,
cultured in vitro, showed a higher IL-1β release after
treatment with LPS alone. These results are consistent
with a deregulation of the IL-1β processing machinery.
Indeed, in patients with cryopyrinopathies, caused by
gain of function NLPR3-mutations, increased IL-1β
release following stimulation with LPS alone is a typical
feature of the disease [9]. IL-1β release can result in
autocrine stimulation and in the secondary induction of
other cytokines, such as IL-6. We indeed found that high
circulating IL-6 levels are present during active disease.
In vivo, neutralization of excessive IL-1β in cryopyri-
nopathies and in deficiency of interleukin-1 receptor
antagonist (DIRA) results in decrease in IL-6 produc-
tion [10-12].
We could not detect circulating IL-1β. However, de-
tection of circulating IL-1β has proven to be extremely
difficult even in diseases in which undoubtedly excessive
IL-1β production is known to be involved, including
cryopirinopathies and systemic JIA [13,14]. Therefore,
the absence of detectable levels of IL-1β does not rule
out a pathogenic role for this cytokine. Indeed, satisfac-
tory responses to anakinra have been reported in one
patient with synovitis-acne-pustulosis-hyperostosis-oste-
itis syndrome (SAPHO) [15], and in two patients with
Majeed syndrome [16]. One transient response has been
reported in one patient with CRMO [17]. These observa-
tions, together with our results, point to a role for IL-1β
in the pathogenesis of CRMO and further support the
inclusion of CRMO in the group of autoinflammatory dis-
eases. The higher mRNA levels of CASP-1 and pro-IL-1β
found in patients during remission suggest the presence of
a sustained proinflammatory state in CRMO patients. The
mechanisms leading to this proinflammatory state, as well
to activation of the inflammasome in vitro hyper-response
are unknown: in particular, possible contribution of genet-
ics have remained unclarified. In addition, we found high
expression of IL-6 in bone biopsies from CRMO patients
(Figure 2GI), suggesting that IL-6 produced at inflamma-
tory sites may be the source of the circulating measurable
cytokine in the blood. Circulating IL-6 levels were sig-
nificantly higher in CRMO patients during active disease.
In cryopirinopathies, in which abnormal IL-1 secretion
drives the cytokine cascade and all clinical and laboratoryfeatures, IL-6 production in tissues and high circu-
lating levels have been shown to be completely IL-1β
dependent [10,18].
We have also shown that osteoclasts in vivo express
inflammasome-related proteins. This is consistent with
data in the literature [19-21] and a publically available
expression profile database, showing detectable mRNA
levels of inflammasome components in osteoclasts dif-
ferentiated in vitro [22]. However, the function of the
inflammasome in osteoclasts is not known yet. In this
respect, future studies in osteoclasts from patients with
Majeed syndrome might represent the ideal model to
investigate, in the context of a genetic abnormality, the
presence of abnormal function of the osteoclasts.
Conclusions
We have shown increased IL-1β secretion by peripheral
blood mononuclear cells of CRMO patients during active
disease and expression of inflammasome components by
CRMO and control osteoclasts in vivo. These results
further support a role for autoinflammation in CRMO.
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